PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 25.19

Change

-0.19 (-0.75)%

Market Cap

N/A

Volume

0.10M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

-0.07 (-0.11%)

USD 10.78B
DOCS Doximity Inc

+0.09 (+0.15%)

USD 10.37B
WEAV Weave Communications Inc

-0.18 (-1.11%)

USD 1.13B
AMWL American Well Corp

+0.19 (+2.55%)

USD 0.15B
MPLN MultiPlan Corporation

+5.96 (+94.90%)

USD 0.12B
OWLT Owlet Inc

-0.02 (-0.43%)

USD 0.08B
TDOC Teladoc Inc

+0.14 (+1.54%)

N/A
FOXO FOXO Technologies Inc.

-0.03 (-9.87%)

N/A
EVH Evolent Health Inc

-0.05 (-0.44%)

N/A
VEEV Veeva Systems Inc Class A

-7.46 (-3.32%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.81% 70% C- 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.81% 70% C- 51% F
Trailing 12 Months  
Capital Gain 10.82% 70% C- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.82% 70% C- 57% F
Trailing 5 Years  
Capital Gain -4.80% 50% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.80% 50% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 11.97% 70% C- 69% C-
Dividend Return 11.97% 70% C- 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 67.37% 60% D- 14% F
Risk Adjusted Return 17.77% 80% B- 33% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector